Peptide HPLC Carryover: How Ghost Peaks Distort Purity Results
A purity figure is only as clean as the injection sequence that produced it. Peptide HPLC carryover happens when a trace of one sample survives in the instrument and turns up in the chromatogram of the sample injected after it. The result looks like an impurity, gets integrated like an impurity, and lowers the reported purity of material that may be perfectly fine. For labs that test many vials from a large order, or run a string of different compounds in one sequence, it is one of the easiest artefacts to create and one of the easiest to overlook.
Where residue hides in the flow path
Every injection travels the same route: into the needle, through the injection valve and sample loop, along the connecting tubing and onto the column. Any part of that route can hold back a small amount of analyte and release it later.
- The needle. Both the inner bore and the outer surface are wetted by the sample. Whatever the wash step fails to remove is carried into the next vial and the next injection.
- The injection valve. Rotor seals wear with use, and scratches or grooves on the seal face trap liquid that is swept out on a later cycle.
- Fittings and tubing. A fitting that is not seated fully leaves a small unswept pocket. Polymer tubing and seals can also hold hydrophobic material by adsorption.
- The column itself. Material that is strongly retained may not leave during the gradient and can bleed off during the following run, often as a broad hump rather than a sharp peak.
Peptides are especially good at exploiting these spots. Positively charged residues such as lysine and arginine bind to exposed silanols and metal surfaces, while long hydrophobic sequences cling to polymer parts. The chemistry that makes a peptide retain strongly on a C18 column is the same chemistry that makes it hard to rinse from the hardware.
Carryover versus other ghost peaks
Not every unexpected peak is carryover. Mobile-phase contamination, a dirty column and genuine sample impurities can all produce extra peaks, and each has a different fix. A short diagnostic sequence usually separates them.
| What you see | Most likely source | How to confirm |
|---|---|---|
| Sharp peak in a solvent blank at the exact retention time of the previous sample’s main peak | Autosampler carryover | Inject two or three blanks in a row; the peak should shrink with each one |
| Same peaks in every blank regardless of what ran before | Mobile phase, water or system contamination | Run the gradient with no injection at all; the peaks remain |
| Broad or late peaks after a strongly retained sample | Column carryover | Add a high-organic wash at the end of the gradient and see whether they disappear |
| Peak that stays proportional to the sample amount and appears in fresh preparations | A real impurity in the material | Re-prepare the sample and inject it after clean blanks |
The retention-time match is the strongest single clue. A true impurity sits wherever its own chemistry puts it; a carried-over peak sits exactly where the last sample’s peak eluted.
Measuring peptide HPLC carryover
The standard test is simple. Inject the most concentrated sample or standard the method will see, follow it immediately with a solvent blank, and compare the area of any peak in the blank at the analyte’s retention time with the area from the concentrated injection. Expressed as a percentage, that ratio is the carryover for that method on that instrument.
Acceptable limits depend on what the method is for. Bioanalytical guidance such as ICH M10 ties the limit to the lowest calibrator, requiring the blank after the highest standard to show no more than 20 percent of the lower limit’s response. For purity work, the useful question is whether the carried-over area is large enough to be reported as an impurity at the method’s reporting threshold. If it is, the method needs attention before its results are trusted.
Carryover is best checked as part of system suitability, so that each sequence starts with evidence that the instrument is clean enough for the job.
Why multi-compound sequences raise the stakes
A laboratory testing one compound at a time has a forgiving situation: residue from lot A of a peptide injected before lot B of the same peptide co-elutes with lot B’s main peak and barely changes the answer. Things change when a sequence runs through several different compounds, which is exactly what happens when a bulk order covering many products goes out for testing together.
In that case, a trace of the previous compound lands at its own retention time in the next chromatogram, well clear of the main peak. It is integrated as an impurity, and it may even be larger than the sample’s real impurities if the previous injection was concentrated. Two practical signs point to this:
- A minor peak in one sample whose retention time matches the main peak of a different compound in the same sequence.
- The same minor peak absent when the sample is re-run on another day, in a different order.
For a procurement or QC team comparing results across many vials, this matters because it can make one lot look inconsistent with the rest when the difference came from the run order, not the material.
Keeping carryover under control
Most of the remedies are routine and cost little more than instrument time:
- Match the wash to the analyte. A mostly aqueous needle wash will not shift a hydrophobic peptide. A wash with a higher organic content, often with a little acid added, is more effective; some labs use a second, stronger wash solvent for sticky compounds.
- Wash more than once. Extra wash cycles, or washing both the inside and outside of the needle where the autosampler allows it, reduce the residue that reaches the next vial.
- Maintain the hardware. Replacing worn rotor seals and remaking loose fittings removes the places liquid can hide.
- Design the sequence. Place blanks between different compounds, run dilute samples before concentrated ones, and avoid injecting more material than the method needs.
- Clean the column. A high-organic step at the end of each gradient helps prevent strongly retained material from surfacing in the next run.
- Consider surfaces. Low-adsorption vials and bio-inert flow paths reduce how much peptide binds to hardware in the first place.
Reading certificates with carryover in mind
When you review a chromatogram from any laboratory, look for impurity peaks that the report does not name or assign, and for small peaks whose retention time lines up with a compound the lab might have run just before. Neither proves carryover, but both justify a question: were solvent blanks injected between samples, and did they come back clean?
Carryover is one of several reasons two reports on the same material can differ, alongside detection wavelength, column choice, gradient and integration settings. Our articles on why certificates of analysis disagree and on peak integration cover those in more depth.
Bulk Peptides products are third-party tested for purity by HPLC, certificates are published for some products on the certificates of analysis page, and vials are matched to their certificate by cap and crimp colour. If you are sending vials from a larger order for your own independent analysis, asking the lab to bracket each compound with blanks is a simple way to make the results comparable from vial to vial.
All material sold by Bulk Peptides is intended only for in-vitro laboratory research and analytical work. It is not a drug or supplement and must not be used in humans or animals.
